Q32 Bio (QTTB) Equity Income (2022 - 2024)

Q32 Bio (QTTB) recorded quarterly Equity Income of -$1.4 million in Q2 2024, down 723.3% quarter-over-quarter from -$176000.0 in Q1 2024.

Q32 Bio (QTTB) Equity Income (2022 - 2024) Analysis & Trends

Q32 Bio's Equity Income history runs 2 years deep, the most recent figure standing at -$1.4 million for Q2 2024.

In Q2 2024, Equity Income changed N/A year-over-year to -$1.4 million; the TTM figure through Mar 2025 stood at -$1.4 million (down 723.3% YoY), while the FY2024 annual figure was -$1.6 million, changed N/A from the prior year.
Equity Income was -$1.4 million for Q2 2024 at Q32 Bio, down from -$176000.0 in the prior quarter.
In the past five years, Equity Income ranged from a high of -$176000.0 in Q1 2024 to a low of -$2.2 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	235,807.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Q32 Bio	167.59 Mn	116.84 Mn	-	-

Download Data